Aldeyra The (ALDX) - Total Liabilities

Latest as of September 2025: $28.56 Million USD

Based on the latest financial reports, Aldeyra The (ALDX) has total liabilities worth $28.56 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore how efficiently does Aldeyra The generate cash to assess how effectively this company generates cash.

Aldeyra The - Total Liabilities Trend (2011–2024)

This chart illustrates how Aldeyra The's total liabilities have evolved over time, based on quarterly financial data. Check financial resilience of Aldeyra The to evaluate the company's liquid asset resilience ratio.

Aldeyra The Competitors by Total Liabilities

The table below lists competitors of Aldeyra The ranked by their total liabilities.

Company Country Total Liabilities
Laiqon AG
XETRA:LQAG
Germany €49.37 Million
Rimoni
TA:RIMO
Israel ILA44.06 Million
Y.C.C. Parts MFG Co Ltd
TW:1339
Taiwan NT$1.15 Billion
Technical Olympic S.A
AT:OLYMP
Greece €42.24 Million
Hyundai E P
KO:089470
Korea ₩317.54 Billion
Rich Honour International Designs Co Ltd
TW:6754
Taiwan NT$2.37 Billion
ALM Equity AB (publ)
ST:ALM
Sweden Skr1.86 Billion
Rorze Systems Corporation
KQ:071280
Korea ₩25.44 Billion

Liability Composition Analysis (2011–2024)

This chart breaks down Aldeyra The's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market value of Aldeyra The.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 2.72 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.58 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.37 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Aldeyra The's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Aldeyra The (2011–2024)

The table below shows the annual total liabilities of Aldeyra The from 2011 to 2024.

Year Total Liabilities Change
2024-12-31 $33.60 Million +17.77%
2023-12-31 $28.53 Million -5.78%
2022-12-31 $30.28 Million +10.52%
2021-12-31 $27.40 Million +14.92%
2020-12-31 $23.84 Million -13.09%
2019-12-31 $27.44 Million +223.80%
2018-12-31 $8.47 Million +85.25%
2017-12-31 $4.57 Million +29.29%
2016-12-31 $3.54 Million +6.36%
2015-12-31 $3.33 Million +32.90%
2014-12-31 $2.50 Million +17.60%
2013-12-31 $2.13 Million -92.16%
2012-12-31 $27.13 Million +946.16%
2011-12-31 $2.59 Million --

About Aldeyra The

NASDAQ:ALDX USA Biotechnology
Market Cap
$95.66 Million
Market Cap Rank
#19343 Global
#4234 in USA
Share Price
$1.59
Change (1 day)
+4.61%
52-Week Range
$1.24 - $5.89
All Time High
$14.85
About

Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated and metabolic diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatm… Read more